[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653980":3},{"organization":4,"outcomesModule":7,"designInfo":24,"detailedDescription":27,"studyPopulation":28,"armGroups":29,"interventions":35,"overallOfficials":41,"centralContacts":45,"locations":51,"responsibleParty":71,"collaborators":74,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":23,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":23,"enrollmentInfo":87,"targetDuration":90,"studyType":91,"phases":23,"briefSummary":92,"conditions":93,"keywords":98,"overallStatus":53,"whyStopped":23,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Ohio State University Comprehensive Cancer Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":23},[9],{"measure":10,"description":11,"timeFrame":12},"Feasibility of obtaining paired tumor samples and serial blood collection","The feasibility rate is defined as the proportion of enrolled patients who obtained paired pre- and post-treatment biopsies with good quality (≥30% cellularity) and were compliant with serial blood samples collection","Up to 3 years",[14,17,20],{"measure":15,"description":16,"timeFrame":12},"Investigator-assessed objective response rate (ORR)","The proportion of patients achieving a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1",{"measure":18,"description":19,"timeFrame":12},"Progression-free survival (PFS","The time from treatment initiation until disease progression or death from any cause",{"measure":21,"description":22,"timeFrame":12},"Overall survival (OS)","The time from treatment initiation until death from any cause",null,{"allocation":23,"interventionModel":23,"interventionModelDescription":23,"primaryPurpose":23,"observationalModel":25,"timePerspective":26,"maskingInfo":23},"COHORT","PROSPECTIVE","The goal of this study is to prospectively and longitudinally collect blood and tumor tissue from patients with relapsed small cell lung cancer (SCLC) receiving standard of care commercial DLL3 T cell engager. The investigators will do a comprehensive multi-omic analysis integrating genomic, transcriptomic, proteomic, and clinical data to investigate mechanisms of resistance, and identify potential therapeutic vulnerabilities.\n\nPrimary objective is to assess the feasibility of obtaining paired tumor samples and serial blood collection in relapsed ES-SCLC patients\n\nSecondary objectives are to characterize longitudinal SCLC tumor-associated markers, including DLL3; evaluate concordance between plasma and tissue, Circulating-Tumor DNA (ctDNA), protomics and explore associations between molecular findings and clinical outcomes.","The sample population will include adult patients with relapsed small cell lung cancer (SCLC) receiving care at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital (OSUCCC - The James).",[30],{"label":31,"type":23,"description":32,"interventionNames":33},"Relapsed SCLC Patients","Blood and tissue samples will be collected at baseline, during treatment, and at disease progression, in concordance with routine clinical visits and imaging assessments.",[34],"Procedure: Biospecimen collection",[36],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":23},"PROCEDURE","Biospecimen collection","Undergo blood and tissue sample collection",[31],[42],{"name":43,"affiliation":5,"role":44},"Asrar Alahmadi, MBBS, MAS-CR","PRINCIPAL_INVESTIGATOR",[46],{"name":47,"role":48,"phone":49,"phoneExt":23,"email":50},"The Ohio State University Comprehensive Cancer Center","CONTACT","800-293-5066","OSUCCCClinicaltrials@osumc.edu",[52],{"facility":5,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"RECRUITING","Columbus","Ohio","43210","United States","US",{"type":60,"coordinates":61},"Point",[62,63],-82.99879,39.96118,{"lat":63,"lon":62},[66,70],{"name":67,"role":48,"phone":68,"phoneExt":23,"email":69},"Asrar Alahamadi, MBBS","614-293-6786","Asrar.Alahmadi@osumc.edu",{"name":43,"role":44,"phone":23,"phoneExt":23,"email":23},{"type":44,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"Asrar Alahmadi","Principal Investigator",[75],{"name":76,"class":77},"Genentech, Inc.","INDUSTRY","100653980","prospective-multiomic-analysis-in-small-cell-lung-cancer-100653980",false,"NCT07795411","Prospective Multiomic Analysis in Small-Cell Lung Cancer","Prospective Multiomic Analysis in Small-Cell Lung Cancer to Inform Therapeutic Vulnerabilities and Predict Clinical Outcomes: Deep Phenotyping of Relapsed SCLC Cohort","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Confirmed pathologic diagnosis of active SCLC or neuroendocrine cancer.\n3. Relapsed small cell lung cancer (SCLC) planning to receive commercial DLL3 bispecific T cell engager.\n4. Willing to provide informed consent.\n5. Willing to provide blood samples and undergo tissue biopsy at various time points throughout the study, collected in concurrence with treatment cycles and\u002For imaging visits\n6. Patients with multiple primary malignancies, recurrent lung cancer, or mixed histology are not excluded.\n7. Patients who have contraindications or are unable to receive immunotherapy will be eligible for the study, and their samples will be used for comparison and control.\n\nExclusion Criteria:\n\n1. Prisoners or incarcerated patients\n2. Those with cognitive impairments lacking decision-making capacity are excluded.\n3. There will be no specific restrictions with respect to performance status, organ function, or prior\u002Fconcurrent modes of therapy other than that the patient must be able to tolerate venipuncture and any planned interventional radiology or surgical procedures deemed necessary by their treating physicians.","ALL","18 Years",{"count":88,"type":89},30,"ESTIMATED","3 Years","OBSERVATIONAL","This is an observational study to collects blood samples and tumor tissue from adults with relapsed small-cell lung cancer (SCLC) receiving standard of care commercial DLL3 T cell engager. The goal of the study is to understand the changes in tumor markers over time and examine whether these changes are associated with clinical outcomes. Participants will provide blood samples and, when clinically feasible, tumor tissue during routine care visits, treatment, and imaging assessments. The study does not assign cancer treatment.",[94,95,96,97],"Small Cell Cancer Of The Lung","Small Cell Lung Cancer ( SCLC )","Lung Cancer","Small-Cell Lung Cancer (SCLC)",[99,100],"relapsed small-cell lung cancer","multiomic analysis","2026-09-29",{"date":103,"type":104},"2026-10-02","ACTUAL",{"date":106,"type":89},"2026-11-25",{"date":108,"type":89},"2028-12-31",{"name":5,"class":6},1]